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Objective. IL2RA/CD25, the gene for interleukin-2
receptor , is emerging as a general susceptibility gene
for autoimmune diseases because of its role in the
development and function of regulatory T cells and the
association of single-nucleotide polymorphisms (SNPs)
within this gene with type 1 diabetes mellitus (DM),
Graves’ disease, rheumatoid arthritis (RA), and multi-
ple sclerosis (MS). The aim of this study was to deter-
mine whether SNPs within the IL2RA/CD25 gene are
associated with juvenile idiopathic arthritis (JIA).
Methods. Three SNPs within the IL2RA/CD25
gene, that previously showed evidence of an association
with either RA, MS, or type 1 DM, were selected for
genotyping in UK JIA cases (n  654) and controls (n 
3,849). Data for 1 SNP (rs2104286) were also available
from North American JIA cases (n  747) and controls
(n  1,161). Association analyses were performed using
Plink software. Odds ratios (ORs) and 95% confidence
intervals (95% CIs) were calculated.
Results. SNP rs2104286 within the IL2RA/CD25
gene was significantly associated with UK JIA cases
(OR for the allele 0.76 [95% CI 0.66–0.88], P for
trend  0.0002). A second SNP (rs41295061) also
showed modest evidence for association with JIA (OR
0.80 [95% CI 0.63–1.0], P  0.05). Association with
rs2104286 was convincingly replicated in the North
American JIA cohort (OR 0.84 [95% CI 0.65–0.99], P for
trend  0.05). Meta-analysis of the 2 cohorts yielded
highly significant evidence of association with JIA (OR
0.76 [95% CI 0.62–0.88], P  4.9  10
5).
Conclusion. These results provide strong evidence
that the IL2RA/CD25 gene represents a JIA susceptibil-
ity locus. Further investigation of the gene using both
genetic and functional approaches is now required.
Juvenile idiopathic arthritis (JIA), the most com-
mon chronic rheumatic disease in children (1), is an
umbrella term for diseases that start before the age of 16
years and are characterized by arthritis that persists for
more than 6 weeks. JIA can be subdivided into 7
clinically more homogeneous subtypes, using the Inter-
national League of Associations for Rheumatology
(ILAR) classification system (2).
The genetic basis of JIA is complex, but it has
been estimated that the sibling recurrence risk (s)i s1 5
(3). The most well-established genetic factor for JIA is
HLA, and associations with HLA class I and class II
genes exist, although both the strength of the associa-
tions and the associated alleles vary between subtypes
(4). Recently, a variant in the coding region of the
PTPN22 gene, which has been found to be associated
with a number of autoimmune diseases, including rheu-
matoid arthritis (RA), type 1 diabetes mellitus (DM),
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251autoimmune thyroid disease (AITD), and systemic lupus
erythematosus (SLE) (5), was identified as a second
susceptibility locus for JIA (6). The effect size for
PTPN22 varies between subtypes but, in general, is
smaller than that for HLA, and it has been hypothesized
that there are additional genetic risk factors for JIA that
remain to be discovered.
Another gene that is emerging as a potential
“autoimmune gene” is IL2RA/CD25. It was initially
identified as a candidate gene for type 1 DM and AITD
(7). Further support has come from recently conducted
genome-wide association studies of RA (8) and multiple
sclerosis (MS) (9) showing that the same SNP,
rs2104286, which lies within intron 1 of the IL2RA/CD25
gene (8), is associated with both diseases. The study in
MS patients also identified an association of an addi-
tional SNP, rs12722489, in linkage disequilibrium with it
(9). More recently, the IL2RA/CD25 region has been
intensely studied in type 1 DM, where large-scale fine-
mapping across the IL2RA/CD25 gene found strong
statistical evidence of association with 2 independent
groups of SNPs (10). In that study, the presence of the
susceptibility alleles was also shown to be correlated
with lower concentrations of soluble interleukin-2 recep-
tor  (IL-2R)/CD25.
The IL2RA/CD25 gene encodes 1 of the subunits
of the IL-2 receptor that binds IL-2 and is vital in the
regulation of T cell function. IL2RA/CD25–knockout
mice develop severe systemic autoimmune disease, a
paradoxical finding suggesting that the gene is needed
for down-regulation of immune responses in order to
prevent autoimmunity. IL-2R/CD25 is the hallmark
antigen of regulatory T cells (11–14), which play a vital
role in the suppression of autoreactive T cells that
escape other methods of tolerance. Depletion of these
cells in mouse models results in the spontaneous devel-
opment of autoimmune diseases (11). Thus, the evi-
dence is building in support of a critical role of the
IL-2/IL-2R–dependent regulatory pathway in the de-
velopment of autoimmunity.
Given the evidence of a role of variation in the
IL2RA/CD25 gene in autoimmune disease susceptibility
provided by the genome-wide association studies of MS
and RA and the fine-mapping of the IL2RA/CD25
region in type 1 DM, we hypothesized that IL2RA/CD25
may also play a role in JIA. The aim of this study,
therefore, was to determine whether IL2RA/CD25 SNPs
previously found to be associated with RA, MS, and type
1 DM are also associated with JIA.
PATIENTS AND METHODS
UK patients and controls. DNA was available for 654
white UK JIA patients from the British Society for Paediatric
and Adolescent Rheumatology (BSPAR) National Repository
for JIA. JIA cases were classified according to ILAR criteria
(15). This is a combined set of all ILAR subtypes, including
systemic-onset JIA (n  115), persistent (n  194) and
extended oligoarthritis (n  86), rheumatoid factor (RF)–
negative (n  138) and RF-positive (n  35) polyarthritis,
enthesitis-related JIA (n  28), psoriatic JIA (n  51), and
cases with peripheral synovitis, which could not be classified
(n  7).
DNA samples from 3,849 healthy white control sub-
jects were available from 5 centers in the UK (16), as follows:
Manchester (n  924), Sheffield (n  995), Leeds (n  532),
Aberdeen (n  862), and Oxford (n  536). All study subjects
were recruited with approval of the local ethics committees
(North-West Multi-Centre Research Ethics Committee
[MREC 99/8/84] and the University of Manchester Committee
on the Ethics of Research on Human Beings) and provided
informed consent.
Genotyping of the UK cohort. Three IL2RA/CD25
SNPs were selected for investigation: rs2104286, rs41295061,
and rs11594656. SNP rs2104286 is the marker at the IL2RA/
CD25 locus that was most strongly associated with RA in the
Wellcome Trust Case Control Consortium (WTCCC) genome-
wide association study (8) and has also been associated with
MS (9). SNPs rs41295061 and rs11594656 are the markers that
were most significantly associated in each of the 2 independent
groups of SNPs identified in the type 1 DM fine-mapping study
of IL2RA/CD25 (10). Genotyping of the UK JIA cases and
controls was performed using the Sequenom iPLEX platform
(Sequenom, San Diego, CA). A 90% sample quality control
rate and a 95% SNP genotyping success rate was imposed on
the analysis.
Genotype data for SNP rs2104286 in the controls were
combined with the data for that SNP obtained in the WTCCC
genome-wide association study (8). The total sample size in the
controls was 6,787.
North American patients and controls. A second co-
hort comprising 747 white North American JIA patients and
1,161 white North American controls was also studied. The
majority of the cases were recruited at the Cincinnati Chil-
dren’s Hospital Medical Center. The medical and clinical data
for these study subjects are available in the Pediatric Rheuma-
tology Research Registry maintained within the William S.
Rowe Division of Rheumatology. The remaining sub-
jects were recruited from collaborating centers across the US.
These collections include the National Institute of Arthritis
and Musculoskeletal and Skin Diseases–supported JIA Af-
fected Sibpair Registry, a national collection of multiplex
families that includes sample collections and clinical informa-
tion. All patients met the ILAR criteria for JIA, which were
assigned retrospectively; therefore, for the purposes of this
study, a patient was considered to be RF-negative based on a
single test. ILAR JIA subtypes in this group of patients
consisted of persistent oligoarthritis (n  325), extended
oligoarthritis (n  105), RF-positive polyarthritis (n  4),
RF-negative polyarthritis (n  312), and systemic-onset JIA
(n  1).
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North American JIA cases had previously been genotyped for
1o ft h eIL2RA/CD25 SNPs, rs2104286, using Affymetrix
GeneChip Human Mapping 500K arrays (Affymetrix, Santa
Clara, CA). This study was approved by the Institutional
Review Board of Cincinnati Children’s Hospital Medical Cen-
ter. Appropriate consent was obtained from the subjects and
their family members or an Institutional Review Board exemp-
tion was granted for legacy samples which predated the current
consent process and which are now de-identified.
The controls comprised 1,161 healthy white individuals
from the New York Cancer Project. The rs2104286 SNP had
not been genotyped directly, but the imputed genotypes were
inferred from multimarker combinations. Only samples with a
95% confidence score for their imputed genotypes were
included (17).
Statistical analysis. Genotype and allele frequencies
were compared between JIA cases and controls using Stata
version 9 SE (StataCorp, College Station, TX) and Plink (18)
software, and odds ratios (ORs) and 95% confidence intervals
(95% CIs) were calculated. Stratification by ILAR subtype,
antinuclear antibody (ANA) status, and sex was performed.
Conditional logistic regression was performed using Plink
software. Haplotype analysis was performed using Haploview
version 4.0 software (19). In addition, the Cochran-Mantel-
Haenszel test was used to perform a meta-analysis of the 2
cohorts, and a test for heterogeneity between cohorts was
performed using the Breslow-Day test.
RESULTS
All SNPs were in Hardy-Weinberg equilibrium in
the UK and North American control cohorts. In the UK
cohort, SNP rs2104286, which lies within the IL2RA/
CD25 gene, was associated with JIA (OR for the allele
0.76 [95% CI 0.66–0.88], P for trend  0.0002) (Table 1).
JIA is a phenotypically heterogeneous disease,
with a female predominance and an association with the
presence of ANAs. Stratification analysis was therefore
performed by ILAR subtype, sex, and the presence or
absence of ANAs. Analysis stratifying by ILAR subtype
(Table 2) showed that the association with SNP
rs2104286 was strongest in both the persistent (OR for
the allele 0.69 [95% CI 0.53–0.89], P for trend  0.005)
and extended (OR for the allele 0.53 [95% CI 0.35–
0.81], P for trend  0.003) oligoarthritis subtypes. The
association of rs2104286 with JIA was also stronger in
the ANA-positive subgroup (OR for the allele 0.65
[95% CI 0.49–0.86], P for trend  0.002) and the female
cases (OR for the allele 0.76 [95% CI 0.64–0.91], P for
trend  0.002) as compared with the controls (Table 2).
Association analysis of the 2 type 1 DM–
associated IL2RA/CD25 SNPs revealed that only 1 of
them, rs41295061, showed borderline evidence of asso-
ciation with JIA as compared with controls (OR for the
allele 0.8 [95% CI 0.63–1.0], P for trend  0.05) (Table
1). Analysis stratifying JIA cases by ILAR subtype
(Table 2) showed no statistically significant differences
between the subtypes. Logistic regression analysis con-
ditioning on the most-associated SNP, rs2104286, sug-
gested that this SNP accounts for the association with
JIA and that the association with rs41295061 is not an
independent association but is due to linkage disequili-
brium with rs2104286 (P  0.62 for rs41295061 after
conditioning on rs2104286), despite only moderate cor-
relation (r
2  0.27). Haplotype analysis for the 2 SNPs
showed that the haplotype of the 2 major alleles of both
SNPs was overrepresented in cases compared with con-
trols (OR 0.77 [95% CI 0.58–0.93], P  0.0035), with an
odds ratio similar to that for the single-marker associa-
tion (OR 0.77 [95% CI 0.66–0.88]).
Genotype frequencies in the North American
JIA cases were similar to those found in the UK cohort.
Comparison of genotype frequencies between North
American cases and controls provided further evidence
of association of rs2104286 with JIA (OR for the allele
0.84 [95% CI 0.65–0.99], P for trend  0.05) (Table 1).
Stratification of the North American JIA cases by ILAR
subtype was performed, and the association was stron-
Table 1. Association of IL2RA/CD25 SNPs in UK JIA cases and controls, and of SNP rs2104286 in North American JIA cases and controls*
Cohort,
marker Chr.
Minor/
major
allele
Genotyping
success rate
(%)
HWE
in
controls
MAF
Genotype frequency, no. (%)
P
for
trend
OR
(95% CI)
for allele
Cases Controls
Cases Controls 11 12 22 11 12 22
UK
rs2104286 10 G/A 96.4 0.88 0.22 0.27 30 (5.1) 207 (34.9) 356 (60) 502 (7.6) 2,621 (39.9) 3,454 (52.5) 0.0002 0.76 (0.66–0.88)
rs41295061 10 A/C 94 0.61 0.07 0.09 2 (0.3) 87 (14.1) 530 (85.6) 32 (0.9) 591 (16.3) 2,991 (82.8) 0.05 0.8 (0.63–1.0)
rs11594656 10 A/T 94 0.56 0.24 0.25 35 (5.7) 223 (36.0) 361 (58.3) 212 (5.9) 1,356 (37.5) 2,046 (56.6) 0.73 0.95 (0.82–1.09)
North American
rs2104286 10 G/A 96.6 0.88 0.23 0.26 34 (4.7) 262 (36.3) 426 (59.0) 70 (6.0) 454 (39.1) 637 (54.9) 0.05 0.84 (0.65–0.99)
* In the UK cohort, there were 654 juvenile idiopathic arthritis (JIA) cases and 3,849 controls. In the North American cohort, there were 747 JIA cases and 1,161 controls.
SNPs  single-nucleotide polymorphisms; Chr.  chromosome; HWE  Hardy-Weinberg equilibrium; MAF  minor allele frequency; OR  odds ratio; 95% CI  95%
confidence interval.
ASSOCIATION OF IL2RA/CD25 WITH JIA 253gest in the persistent oligoarthritis subtype (OR for the
allele 0.83 [95% CI 0.59–1.03], P for trend  0.09)
(Table 2).
There was no significant evidence of heterogen-
eity between the UK and North American data sets.
Meta-analysis of the 2 cohorts yielded highly significant
evidence of association (OR 0.76 [95% CI 0.62–0.88],
P  4.9  10
5).
DISCUSSION
In this study, we found significant evidence of
association of a polymorphism within the IL2RA/CD25
gene with JIA in 2 independent cohorts. SNPs within
the IL2RA/CD25 gene have previously been associated
with a number of other autoimmune diseases, including
type 1 DM (10), Graves’ disease (20), and MS (9). In
addition, a rare mutation of the IL2RA/CD25 gene can
lead to the development of a severe autoimmune disease
characterized by decreased numbers of peripheral T
cells displaying abnormal proliferation, with extensive
lymphocytic infiltration of tissues accompanied by tissue
atrophy and inflammation, but normal B cell develop-
ment (21). The finding of an association with JIA further
extends the evidence that variation across this gene
predisposes to autoimmunity in general.
The concept of “autoimmune genes” is not novel.
Previous analysis of linkage studies in a number of
autoimmune diseases showed evidence of overlap be-
tween regions of linkage (22). Furthermore, there is
precedent for this because the PTPN22 gene has been
associated with a variety of autoimmune diseases, al-
though, interestingly and unlike the IL2RA/CD25 gene,
not with MS.
Three SNPs were selected for genotyping based
on their association with other autoimmune diseases,
and 2 of these SNPs were associated with JIA in the
current study. The strongest effect was seen with
rs2104286 (OR for minor allele 0.76 [95% CI 0.66–
0.88]), which is comparable to the ORs calculated for
MS (OR 0.81 [95% CI 0.74–0.89]) and RA (OR 0.81
[95% CI 0.73–0.89]). This SNP maps to intron 1 of the
IL2RA/CD25 gene, and was selected for genotyping
because recent genome-wide association studies of both
RA and MS found an association with the same variant
(rs2104286). In addition, the MS study also found an
association with a SNP in strong linkage disequilibrium
with it, rs12722489 (9).
The other 2 SNPs genotyped in this study of JIA
were selected based on recent studies of the IL2RA/
CD25 region in type 1 DM (10). Fine-mapping studies
detected an association with 2 independent groups
of SNPs spanning overlapping regions of 14 kb and
40 kb, encompassing IL2RA/CD25 intron 1 and the
5-intergenic region between IL2RA/CD25 and RBM17.
Table 2. Association analysis of IL2RA/CD25 SNPs in UK and North American JIA cases stratified by ILAR-classified subtype, and in UK JIA
cases and controls stratified by ANA status and sex*
No. of
cases
No. of
controls
rs2104286 rs41295061 rs11594656
P for
trend
OR (95% CI)
for allele
P for
trend
OR (95% CI)
for allele
P for
trend
OR (95% CI)
for allele
UK cohort
JIA subtype, by ILAR criteria
Systemic 115 – 0.11 0.77 (0.56–1.1) 0.16 0.67 (0.39–1.17) 0.92 0.98 (0.72–1.34)
Persistent oligoarthritis 194 – 0.005 0.69 (0.53–0.89) 0.15 0.73 (0.49–1.11) 0.82 1.03 (0.81–1.31)
Extended oligoarthritis 86 – 0.003 0.53 (0.35–0.81) 0.11 0.57 (0.29–1.13) 0.61 0.91 (0.63–1.31)
RF-negative polyarthritis 138 – 0.57 0.92 (0.68–1.23) 0.52 1.14 (0.76–1.73) 0.43 0.88 (0.66–1.19)
Psoriatic 51 – 0.43 0.83 (0.52–1.32) 0.47 0.75 (0.35–1.63) 0.75 1.07 (0.69–1.69)
ANA status
Positive 177 6,787 0.002 0.65 (0.49–0.86) 0.16 0.73 (0.48–1.13) 0.3 0.86 (0.64–1.15)
Negative 358 6,787 0.06 0.84 (0.7–1.0) 0.56 1.08 (0.84–1.38) 0.49 0.94 (0.78–1.13)
Sex
Female 466 3,902 0.002 0.76 (0.64–0.91) 0.47 0.91 (0.69–1.18) 0.04 0.83 (0.69–0.99)
Male 207 2,675 0.05 0.78 (0.61–1.0) 0.02 0.59 (0.37–0.92) 0.06 1.25 (0.98–1.59)
North American cohort
JIA subtype, by ILAR criteria
Persistent oligoarthritis 325 – 0.09 0.83 (0.59–1.03) – – – –
Extended oligoarthritis 105 – 0.85 0.97 (0.57–1.26) – – – –
RF-negative polyarthritis 312 – 0.21 0.86 (0.6–1.07) – – – –
* SNPs  single-nucleotide polymorphisms; JIA  juvenile idiopathic arthritis; ILAR  International League of Associations for Rheumatology;
ANA  antinuclear antibody; OR  odds ratio; 95% CI  95% confidence interval; RF  rheumatoid factor.
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tinguishable SNPs, the most strongly associated being
rs41295061, while the second group comprised 3 indis-
tinguishable SNPs, the most strongly associated being
rs11594656. Both of these SNPs are potentially func-
tional, given that genotypes at each have been corre-
lated with lower concentrations of soluble IL-2R/
CD25. This suggests that a reduction in immune activa-
tion may predispose to type 1 DM (10) and, indeed,
other autoimmune diseases.
Interestingly, in the present study, only 1 of the 2
SNPs associated with type 1 DM (rs41295061) showed a
weak association with JIA. The evidence of association
with this SNP was stronger when genotype frequencies
from the JIA cases were compared with those in the
large type 1 DM control cohort (n  6,855) (OR for the
allele 0.69 [95% CI 0.55–0.85], P for the genotype 
0.002), while that of the second SNP (rs11594656) re-
mained nonsignificant (OR for the allele 0.94 [95% CI
0.82–1.08], P for the genotype  0.4). Association of the
type 1 DM intron 1 SNP (rs41295061) with JIA was not
as strong as with SNP rs2104286, and this association
requires validation in an additional cohort. Hence, it will
be vital to determine whether the genotype at the
rs2104286 locus also correlates with soluble IL-2R/
CD25 levels or any other functional effect.
Examination of linkage disequilibrium between
the SNPs tested in this study suggested that there is low
linkage disequilibrium between rs2104286 and the 2
SNPs (rs41295061 and rs11594656) identified in the type
1 DM fine-mapping study (r
2  0.27 and r
2  0.03,
respectively). However, logistic regression analysis of
the 3 SNPs conditioning on the most-associated SNP,
rs2104286, suggests that this is the SNP that drives the
association with JIA. The association with rs41295061 is
due to linkage disequilibrium with rs2104286. Further
investigation of SNPs across the IL2RA/CD25 gene will
now be required to identify the causal variant.
The association with rs2104286 was confirmed in
an independent cohort of North American JIA cases and
controls (OR 0.84 [95% CI 0.65–0.99], P for trend 
0.05). Meta-analysis of the 2 data sets strengthened the
effect (OR 0.76 [95% CI 0.62–0.88], P  4.9  10
5),
thereby providing further support for the role of IL2RA/
CD25 in susceptibility to JIA.
False-positive associations can arise as a result of
population stratification. The WTCCC study (8) previ-
ously established that there was very little evidence of
this across the UK. We did not test the North American
data for population stratification. However, there was no
evidence of heterogeneity between the 2 populations as
assessed by the Breslow-Day test. Furthermore, the fact
that the genotype/allele frequencies for the associated
markers were very similar in the UK and the North
American case and control populations suggests that the
detected association is genuine.
JIA is a phenotypically heterogeneous disease.
Thus, although it may be argued that stratification
analysis may result in inflated Type I error rates because
of multiple testing, the creation of more homogenous
subgroups may increase the power to detect an associa-
tion. In the current study, evidence of an association
with rs2104286 was strongest in the oligoarthritis sub-
types, female cases, and JIA cases with ANAs. The
association with all these subgroups is not surprising,
since the phenotypes are correlated. The same subgroup
effect does appear to be true for rs41295061. However,
it should be noted that the small sample sizes in some of
the ILAR subtypes may have limited the ability to draw
robust conclusions about association of the IL2RA/CD25
SNPs with those phenotypes. Comparison of rs2104286
SNP allele frequencies between the 5 subtypes suggests
that they are not statistically different (P  0.28).
Therefore, larger sample sizes will be required to be able
to clarify association across the individual subtypes.
The IL2RA/CD25 gene was a strong candidate
JIA susceptibility gene not only because of the previous
evidence of association with a variety of other auto-
immune diseases, but also because of its role in the T cell
signaling pathway, which is thought to play a key role in
mediating the inflammatory autoimmune response in
JIA. IL-2, the T cell growth factor, exerts its effect on
T cells through binding with the IL-2R. The IL-2 re-
ceptor is composed of 3 chains, , , and , the -chain
being encoded by the IL2RA/CD25 gene. The  and 
chains are involved in the binding of IL-2, and the  and
 chains are involved in signal transduction once IL-2
has bound. IL-2R/CD25 is central to immune regula-
tion via its role in the development and function of
regulatory T cells. These cells are increasingly seen as
playing a central role in self tolerance. CD4CD25
Treg cells suppress activated T cells, and this immune
suppression is vital in preventing autoimmune diseases.
Hence, variation in the gene encoding IL-2R/CD25
could have profound effects in the predisposition to
autoimmune disease.
A recent study investigated CD4CD25 Treg
cells in children with persistent oligoarthritis (1–4 joints
affected at diagnosis and throughout the disease course)
and extended oligoarthritis (a more destructive disease
ASSOCIATION OF IL2RA/CD25 WITH JIA 255course in which the number of affected joints increases
beyond 4 within 6 months of disease onset), hypothesiz-
ing that Treg cells may play a role in the reversal of the
autoimmune disease process in patients with persistent
oligoarticular JIA (23). It was shown that the number of
CD4
CD25
bright Treg cells at the site of inflammation
(i.e., the joints) was enriched compared with the number
in the peripheral blood. In addition, there was a greater
frequency of CD4
CD25
bright Treg cells in patients with
persistent oligoarthritis as compared with those with
extended oligoarthritis. CD4
CD25
bright Treg cells in
the synovial fluid (SF) showed higher expression of
many activation markers, such as FoxP3, CTLA-4, and
HLA–DR, suggesting that they are more functionally
mature than those in the peripheral blood. These cells
also showed an increased suppressive capacity in vitro
compared with cells from the peripheral blood (23). A
more recent study also found that the ratio of Treg cells
to activated T cells was higher in patients with oligoar-
thritis than in patients with polyarthritis (24). Similar
findings in RA have been reported, with higher numbers
of Treg cells and concomitantly increased suppressive
activity found in SF compared with peripheral blood
cells (25). Thus, there appear to be functional differ-
ences in Treg cells across JIA subtypes.
Interestingly, when we analyzed the IL2RA/CD25
SNPs by JIA subtype, the strongest association was in
both oligoarthritis subtypes, although the limited sample
sizes of some of the other subtypes make conclusions
about subtype-specific associations difficult. In future
studies, we will examine correlations between Treg cell
function and IL2RA/CD25 genotype.
The IL-2 receptor has already been a potential
target of immunologic therapy in autoimmune diseases.
For example, IL-2–directed immunotherapies have been
successful in ameliorating disease in experimental auto-
immune encephalomyelitis, an animal model of MS (26).
In human MS, a monoclonal antibody that binds to the
-chain of IL-2R has been shown to have some thera-
peutic benefits, although its mechanism of action is
unknown (27).
In summary, we identified a putative novel JIA
susceptibility gene, IL2RA/CD25. The association of
IL2RA/CD25 with a fifth autoimmune disease suggests
that this gene, along with the PTPN22 gene, appears to
play a vital role in immune regulation and function as
well as predisposition to autoimmunity in general. Fur-
ther investigation of the gene using both genetic and
functional approaches is now required.
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